Intervention

Ocrelizumab

ClinicalTrials.gov intervention label

Clinical trials68
Recruiting7
Common conditions25
Lead sponsors shown15

Clinical trials

60 shown
Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple SclerosisNCT07827586 · 2026-09-30
RECRUITING
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)NCT07282574 · 2026-03-10
RECRUITING
Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple SclerosisNCT07389590 · 2026-02-10
RECRUITING
A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple SclerosisNCT07321093 · 2025-11-01
RECRUITING
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.NCT06846281 · 2025-06-23
RECRUITING
An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab TreatmentNCT06675955 · 2024-12-13
RECRUITING
A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)NCT06780150 · 2024-09-26
RECRUITING
IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple SclerosisNCT06677710 · 2026-06-30
SUSPENDED
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple SclerosisNCT07483450 · 2025-07-04
ACTIVE_NOT_RECRUITING
Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple SclerosisNCT06495593 · 2025-02-04
ENROLLING_BY_INVITATION
Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMSNCT05974852 · 2023-10-01
COMPLETED
Effect of Ocrelizumab on Cortical Lesion Accumulation in Patients With PPMS (ORATORIO-Cortical)NCT05974839 · 2023-10-01
COMPLETED
A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple SclerosisNCT05208840 · 2023-09-15
WITHDRAWN
Ocrelizumab Discontinuation in Relapsing Multiple SclerosisNCT05285891 · 2023-02-07
ACTIVE_NOT_RECRUITING
Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the GulfNCT05266469 · 2022-07-26
COMPLETED
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)NCT05123703 · 2022-05-19
ACTIVE_NOT_RECRUITING
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple SclerosisNCT05269004 · 2022-05-03
ACTIVE_NOT_RECRUITING
B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple SclerosisNCT05296161 · 2022-04-20
ACTIVE_NOT_RECRUITING
A Study Evaluating B Cell Levels In Infants Potentially Exposed To Ocrelizumab During PregnancyNCT04998812 · 2022-04-13
COMPLETED
LONG-TERM EFFECTIVENESS AND SAFETY EVALUATION OF OCRELIZUMABNCT05210621 · 2022-03-08
ACTIVE_NOT_RECRUITING
Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.NCT04877457 · 2022-02-15
TERMINATED
Ocrelizumab Access by Socio-Economic StatusNCT05131984 · 2021-11-18
COMPLETED
Investigation of the Effect of Ocrelizumab on Peripheral Lymphocyte Immunophenotypes with Suppressive Capacity in MSNCT04874597 · 2021-11-15
UNKNOWN
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their BabiesNCT05688436 · 2021-09-24
ACTIVE_NOT_RECRUITING
A Study Evaluating B Cell Levels In Infants Of Lactating Women With CIS Or MS Receiving OcrelizumabNCT04998851 · 2021-09-16
COMPLETED
Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled TrialNCT04971005 · 2021-08-27
TERMINATED
Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple SclerosisNCT04676555 · 2021-05-11
COMPLETED
Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple SclerosisNCT04688788 · 2021-04-28
ACTIVE_NOT_RECRUITING
Effects of Ocrevus in Relapsing Multiple SclerosisNCT04387734 · 2021-02-05
ACTIVE_NOT_RECRUITING
Safety and Efficacy of Cladribine Therapy After Anti CD20 TherapyNCT04640818 · 2020-12-17
UNKNOWN
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)NCT04548999 · 2020-12-03
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)NCT04544436 · 2020-11-26
ACTIVE_NOT_RECRUITING
Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS DiseaseNCT04578639 · 2020-11-02
ACTIVE_NOT_RECRUITING
Symptom Burden in Patients Treated With Ocrelizumab for Multiple SclerosisNCT04855617 · 2020-10-26
COMPLETED
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple SclerosisNCT04544449 · 2020-10-26
ACTIVE_NOT_RECRUITING
Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis OnsetNCT04466150 · 2020-08-30
ACTIVE_NOT_RECRUITING
Ocrelizumab in BreastmilkNCT04387110 · 2020-08-07
COMPLETED
Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple SclerosisNCT04261790 · 2020-08-01
COMPLETED
Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With OcrelizumabNCT04377555 · 2020-07-30
COMPLETED
Mechanistic Study of OcrevusNCT04459988 · 2020-07-01
COMPLETED
A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple SclerosisNCT04075266 · 2020-01-09
ACTIVE_NOT_RECRUITING
A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple SclerosisNCT03972306 · 2019-08-12
COMPLETED
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple SclerosisNCT04035005 · 2019-08-12
ACTIVE_NOT_RECRUITING
Ocrelizumab Effects on the Metabolome in MSNCT03873389 · 2019-06-12
COMPLETED
Short-term B-cell Depletion in Relapsing Multiple SclerosisNCT03853746 · 2019-04-01
COMPLETED
Real-world Data of Ocrelizumab in Multiple Sclerosis in LATAMNCT03784547 · 2019-02-01
UNKNOWN
Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple SclerosisNCT03593590 · 2018-11-12
COMPLETED
Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714NCT03691077 · 2018-11-11
UNKNOWN
Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With OcrevusNCT03562975 · 2018-07-23
COMPLETED
This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)NCT03599245 · 2018-07-12
COMPLETED
A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple SclerosisNCT03523858 · 2018-05-28
ACTIVE_NOT_RECRUITING
Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS)NCT03477500 · 2018-03-21
ACTIVE_NOT_RECRUITING
Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple SclerosisNCT03025269 · 2017-11-15
COMPLETED
Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)NCT03085810 · 2017-03-24
TERMINATED
Safety of Switching From Rituximab to Ocrelizumab in MS PatientsNCT02980042 · 2017-01-01
COMPLETED
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)NCT02861014 · 2016-09-09
COMPLETED
Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)NCT02688985 · 2016-04-29
COMPLETED
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)NCT02637856 · 2016-02-11
COMPLETED
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple SclerosisNCT01412333 · 2011-09-20
COMPLETED
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple SclerosisNCT01247324 · 2011-08-31
COMPLETED

Common conditions

Multiple Sclerosis32Multiple Sclerosis, Relapsing-Remitting7Relapsing Multiple Sclerosis7Primary Progressive Multiple Sclerosis6Rheumatoid Arthritis5Clinically Isolated Syndrome4Multiple Sclerosis, Primary Progressive4Relapsing Remitting Multiple Sclerosis3Relapsing-Remitting Multiple Sclerosis3Autoimmune Diseases2Demyelinating Diseases2Immune System Diseases2Nervous System Diseases2Autoimmune Diseases of the Nervous System1Demyelinating Autoimmune Diseases, Central Nervous System (CNS)1Multiple Sclerosis (MS)1Multiple Sclerosis, Relapsing1Non-Active Secondary Progressive Multiple Sclerosis1Non-Active SPMS1Pathologic Processes1Primary Progressive Multiple Sclerosis (PPMS)1Progressive Multiple Sclerosis1Progressive Multiple Sclerosis (PMS)1Radiologically Isolated Syndrome1Relapse1

Trial status mix

COMPLETED27
ACTIVE_NOT_RECRUITING18
TERMINATED8
RECRUITING7
UNKNOWN4
ENROLLING_BY_INVITATION1
NO_LONGER_AVAILABLE1
SUSPENDED1
WITHDRAWN1

Phase mix

PHASE327
PHASE414
PHASE26
PHASE13

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.